Dataset Information

Pre-transplant microvesicle proteomics

ABSTRACT: Pre-transplant sera from patients prior to heart transplant

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Serum

DISEASE(S): Heart Disease

SUBMITTER: Barry Fine

LAB HEAD: Barry Fine

PROVIDER: PXD031426 | Pride | 2022-10-14

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	tk160908_BarryFine_BF365_TMT.xlsx	Xlsx
	tk160908_BarryFine_TMT_set1_Frac1_01.raw	Raw
	tk160908_BarryFine_TMT_set1_Frac1_02.raw	Raw
	tk160908_BarryFine_TMT_set1_Frac2_01.raw	Raw
	tk160908_BarryFine_TMT_set1_Frac2_02.raw	Raw

Items per page:

1 - 5 of 130

Publications

Alterations in the kallikrein-kinin system predict death after heart transplant.

Giangreco Nicholas P NP Lebreton Guillaume G Restaino Susan S Farr Maryjane M Zorn Emmanuel E Colombo Paolo C PC Patel Jignesh J Soni Rajesh Kumar RK Leprince Pascal P Kobashigawa Jon J Tatonetti Nicholas P NP Fine Barry M BM

Scientific reports 20220819 1

Heart transplantation remains the definitive treatment for end stage heart failure. Because availability is limited, risk stratification of candidates is crucial for optimizing both organ allocations and transplant outcomes. Here we utilize proteomics prior to transplant to identify new biomarkers that predict post-transplant survival in a multi-institutional cohort. Microvesicles were isolated from serum samples and underwent proteomic analysis using mass spectrometry. Monte Carlo cross-validat ...[more]

PMID: 35986069

Similar Datasets

Project description:Recurrence of focal segmental glomerulosclerosis (rFSGS) after kidney transplantation is a cause of early and accelerated graft loss. Immuneadsorption can alleviate renal dysfunction and suggests that circulating antibodies (Ab) are likely implicated in disease pathogenesis. To evaluate pathogenic Ab in rFSGS, we processed 141 unique serum samples from patients with and without primary rFSGS (n=64) and 34 non-FSGS control, transplanted at five (US and EU) hospitals. 9000 antigens were screened in pre-transplant sera by protein arrays and 10 Ab targeting glomerular antigens were selected for ELISA validation. A panel of 7 Ab (CD40, PTPRO, CGB-5, FAS, P2RY11, SNRPB2 and APOL2) could predict post-transplant FSGS recurrence with 92% accuracy. Pre-transplant elevation of anti-CD40 Ab levels alone had a substantial impact (78% accuracy) on the identification of rFSGS risk after transplantation. Epitope mapping of CD40 with customized peptide arrays and rFSGS sera demonstrated altered immunogenicity of the extracellular CD40 domain in rFSGS. Immunohistochemistry of CD40 demonstrated a differential expression of these antigens in FSGS compared to non-FSGS. Anti-CD40 Ab purified from rFSGS patients were uniquely pathogenic in human podocyte cultures; injection of these Ab resulted in heightened proteinuria, independently and in combination with suPAR in a rodent model, abrogated by injection of monoclonal Ab to CD40. In conclusion, a panel of 7 Ab can identify primary FSGS patients at high risk of recurrence prior to transplantation, allowing for customized therapies and improved patient selection for transplant. Intra-renal CD40 is an important axis of disease pathogenesis, and human trials of anti-CD40 therapies are warranted to evaluate their efficacy in preventing rFSGS and improving graft survival. The purpose of the study was to identify potential auto-Abs associated with rFSGS. We used a discovery set of pre-transplant sera from 20 unique patients with biopsy confirmed diagnosis of primary FSGS as their cause of ESRD, of which 10 had progressed to rFSGS within the first post-transplant year and 10 did not have recurrence of proteinuria or histological disease after transplantation (nrFSGS).